KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $6.0 million.

  • Bionano Genomics' Accounts Payables fell 3114.94% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 3114.94%. This contributed to the annual value of $7.0 million for FY2024, which is 3295.45% down from last year.
  • Bionano Genomics' Accounts Payables amounted to $6.0 million in Q3 2025, which was down 3114.94% from $6.2 million recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Accounts Payables ranged from a high of $15.8 million in Q1 2023 and a low of $2.2 million during Q1 2021
  • Over the past 5 years, Bionano Genomics' median Accounts Payables value was $8.7 million (recorded in 2024), while the average stood at $8.8 million.
  • Per our database at Business Quant, Bionano Genomics' Accounts Payables soared by 26754.27% in 2021 and then tumbled by 4339.25% in 2024.
  • Bionano Genomics' Accounts Payables (Quarter) stood at $10.8 million in 2021, then grew by 16.39% to $12.5 million in 2022, then fell by 17.15% to $10.4 million in 2023, then plummeted by 32.95% to $7.0 million in 2024, then fell by 13.96% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q3 2025, $6.2 million for Q2 2025, and $6.6 million during Q1 2025.